Skip to main content
SpringerLink
Log in
Book cover

Primary Central Nervous System Tumors pp 55–84Cite as

Principles of Supportive Care

  • Chapter
  • First Online:

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

The supportive care of patients who have brain tumors consists mainly of the treatment of seizures, peritumoral edema, venous thromboembolism, fatigue, and cognitive dysfunction. Effective medical management results in decreased morbidity and mortality and improved quality of life for affected patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Fishman RA. Brain edema. N Engl J Med. Oct 2 1975;293 14:706–11.

    CAS  PubMed  Google Scholar 

  2. Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience 2004;129 4:1011–20.

    CAS  PubMed  Google Scholar 

  3. Bates DO, Lodwick D, Williams B. Vascular endothelial growth factor and microvascular permeability. Microcirculation Jun 1999;6 2:83–96.

    CAS  PubMed  Google Scholar 

  4. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. Oct–Nov 2000;50 1–2:109–20.

    CAS  PubMed  Google Scholar 

  5. Bauer AT, Burgers HF, Rabie T, Marti HH. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab. Apr 2010;30(4):837–48.

    Google Scholar 

  6. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery Apr 2000;46 4:938–47. discussion 947–938.

    CAS  PubMed  Google Scholar 

  7. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer Jun 15 2002;94 12:3210–18.

    CAS  PubMed  Google Scholar 

  8. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. Apr 2003;17 6:752–4.

    CAS  PubMed  Google Scholar 

  9. Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol. Jan 2001;280 1:H434–H40.

    CAS  PubMed  Google Scholar 

  10. Nico B, Mangieri D, Tamma R, et al. Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. Eur J Cancer. Dec 2009;45 18:3315–25.

    CAS  PubMed  Google Scholar 

  11. Wang F, Feng XC, Li YM, Yang H, Ma TH. Aquaporins as potential drug targets. Acta Pharmacol Sin. Apr 2006;27 4:395–401.

    CAS  PubMed  Google Scholar 

  12. Nag S, Manias JL, Stewart DJ. Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol. Aug 2009;118 2:197–217.

    PubMed  Google Scholar 

  13. Ludwig HC, Feiz-Erfan I, Bockermann V, Behnke-Mursch J, Schallock K, Markakis E. Expression of nitric oxide synthase isozymes (NOS I–III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas. Anticancer Res. Jan–Feb 2000;20 1A:299–304.

    CAS  PubMed  Google Scholar 

  14. Lafuente JV, Adan B, Alkiza K, Garibi JM, Rossi M, Cruz-Sanchez FF. Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci. Aug–Oct 1999;13 1–2:177–85.

    CAS  PubMed  Google Scholar 

  15. Ilhan A, Gartner W, Neziri D, et al. Angiogenic factors in plasma of brain tumour patients. Anticancer Res. Feb 2009;29 2:731–6.

    CAS  PubMed  Google Scholar 

  16. Ludwig HC, Ahkavan-Shigari R, Rausch S, et al. Oedema extension in cerebral metastasis and correlation with the expression of nitric oxide synthase isozymes (NOS I–III). Anticancer Res. Jan–Feb 2000;20 1A:305–10.

    CAS  PubMed  Google Scholar 

  17. Groves MD, Hess KR, Puduvalli VK, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. Sep 2009;94 2:229–34.

    CAS  PubMed  Google Scholar 

  18. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol. Jul 1994;4 3:207–18.

    CAS  PubMed  Google Scholar 

  19. Matsuda M, Yoneda S, Handa H, Gotoh H. Cerebral hemodynamic changes during plateau waves in brain-tumor patients. J Neurosurg. Apr 1979;50 4:483–8.

    CAS  PubMed  Google Scholar 

  20. Damek DM. Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. Emerg Med Clin North Am. May 2009;27 2:209–29.

    PubMed  Google Scholar 

  21. Gerstner ER, Duda DG, di Tomaso E, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. Apr 2009;6 4:229–36.

    CAS  PubMed  Google Scholar 

  22. Ingraham FD, Matson DD, Mc LR. Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. N Engl J Med. Apr 10 1952;246 15:568–71.

    CAS  PubMed  Google Scholar 

  23. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet. Feb 1961;81:46–53.

    CAS  PubMed  Google Scholar 

  24. French LA, Galicich JH. The use of steroids for control of cerebral edema. Clin Neurosurg. 1964;10:212–23.

    CAS  PubMed  Google Scholar 

  25. Gu YT, Qin LJ, Qin X, Xu F. The molecular mechanism of dexamethasone-mediated effect on the blood–brain tumor barrier permeability in a rat brain tumor model. Neurosci Lett. Mar 13 2009;452 2:114–8.

    CAS  PubMed  Google Scholar 

  26. Kim H, Lee JM, Park JS, et al. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood–brain barrier. Biochem Biophys Res Commun. Jul 18 2008;372 1:243–8.

    PubMed  Google Scholar 

  27. Batchelor T, DeAngelis LM. Medical management of cerebral metastases. Neurosurg Clin N Am. Jul 1996;7 3:435–46.

    CAS  PubMed  Google Scholar 

  28. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose–effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology Apr 1994;44 4:675–80.

    CAS  PubMed  Google Scholar 

  29. Vick NA, Wilson CB. Total care of the patient with a brain tumor with consideration of some ethical issues. Neurol Clin. Nov 1985;3 4:705–10.

    CAS  PubMed  Google Scholar 

  30. Zaki HS, Jenkinson MD, Du Plessis DG, Smith T, Rainov NG. Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir (Wien). Aug 2004;146 8:841–5.

    CAS  Google Scholar 

  31. Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol. Feb 2006;27 2:402–8.

    CAS  PubMed  Google Scholar 

  32. Rabinstein AA. Treatment of cerebral edema. Neurologist Mar 2006;12 2:59–73.

    PubMed  Google Scholar 

  33. Gomes JA, Stevens RD, Lewin JJ 3rd, Mirski MA, Bhardwaj A. Glucocorticoid therapy in neurologic critical care. Crit Care Med. Jun 2005;33 6:1214–24.

    CAS  PubMed  Google Scholar 

  34. Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann Pharmacother. May 1996;30 5:520–6.

    CAS  PubMed  Google Scholar 

  35. Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry. Oct 1984;47 10:1087–90.

    CAS  PubMed  Google Scholar 

  36. Weissman DE, Dufer D, Vogel V, Abeloff MD. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol. 1987;5 2:125–8.

    CAS  PubMed  Google Scholar 

  37. Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J. Oct 1968;123 4:158–73.

    CAS  PubMed  Google Scholar 

  38. Adachi JD, Bensen WG, Cividino A. Corticosteroid-induced osteoporosis. J Am Med Womens Assoc. Winter 1998;53 1:25–30.

    CAS  PubMed  Google Scholar 

  39. Gebhard KL, Maibach HI. Relationship between systemic corticosteroids and osteonecrosis. Am J Clin Dermatol. 2001;2 6:377–88.

    CAS  PubMed  Google Scholar 

  40. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab. Jan 1982;54 1:131–8.

    CAS  PubMed  Google Scholar 

  41. Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S. Effect of high-dose cortisol on memory functions. Ann N Y Acad Sci. Jul 2006;1071:434–7.

    CAS  PubMed  Google Scholar 

  42. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. May 1 1991;114 9:735–40.

    CAS  PubMed  Google Scholar 

  43. Warshaw AL, Welch JP, Ottinger LW. Acute perforation of the colon associated with chronic corticosteroid therapy. Am J Surg. Apr 1976;131 4:442–6.

    CAS  PubMed  Google Scholar 

  44. Davies AN, Brailsford S, Beighton D. Corticosteroids and oral candidosis. Palliat Med. Nov 2001;15 6:521.

    CAS  PubMed  Google Scholar 

  45. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. Nov–Dec 1989;11 6:954–63.

    CAS  PubMed  Google Scholar 

  46. Carson JL, Strom BL, Schinnar R, Duff A, Sim E. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med. Sep 1991;91 3:223–8.

    CAS  PubMed  Google Scholar 

  47. Norden AD, Drappatz J, Ciampa AS, et al. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. Feb 2009;11 1:92–5.

    PubMed  Google Scholar 

  48. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology May 1997;48 5:1234–8.

    CAS  PubMed  Google Scholar 

  49. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology Aug 1991;41 8:1235–9.

    CAS  PubMed  Google Scholar 

  50. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. Jan–Feb 2005;57 1:23–34.

    CAS  PubMed  Google Scholar 

  51. van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. Sep 1994;45 3:114–22.

    PubMed  Google Scholar 

  52. Vecht CJ. Steroid myopathy in cancer patients. Neurology Sep 1998;51 3:918.

    CAS  PubMed  Google Scholar 

  53. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. Oct 2002;13 10:777–87.

    PubMed  Google Scholar 

  54. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. Jun 2000;15 6:993–1000.

    PubMed  Google Scholar 

  55. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. Jul 15 1998;102 2:274–82.

    CAS  PubMed  Google Scholar 

  56. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. Jul 2003;15 4:454–7.

    CAS  PubMed  Google Scholar 

  57. van Brussel MS, Bultink IE, Lems WF. Prevention of glucocorticoid-induced osteoporosis. Expert Opin Pharmacother. Apr 2009;10 6:997–1005.

    PubMed  Google Scholar 

  58. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthr Rheum. Jul 2001;44 7:1496–503.

    Google Scholar 

  59. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol. Feb 2007;26 2:144–53.

    PubMed  Google Scholar 

  60. Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000;2:CD001347.

    PubMed  Google Scholar 

  61. Tascioglu F, Colak O, Armagan O, Alatas O, Oner C. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int. Nov 2005;26 1:21–29.

    CAS  PubMed  Google Scholar 

  62. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. May 2000;15 5:944–51.

    CAS  PubMed  Google Scholar 

  63. Lavelle W, Carl A, Lavelle ED, Khaleel MA. Vertebroplasty and kyphoplasty. Med Clin North Am. Mar 2007;91 2:299–314.

    PubMed  Google Scholar 

  64. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. Aug 6 2009;361 6:557–68.

    CAS  PubMed  Google Scholar 

  65. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. Nov 1983;5 4:319–32.

    CAS  PubMed  Google Scholar 

  66. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. Oct 2006;81 10:1361–7.

    CAS  PubMed  Google Scholar 

  67. Wada K, Yamada N, Sato T, et al. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics Nov–Dec 2001;42 6:461–6.

    CAS  PubMed  Google Scholar 

  68. Hall RC, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis. Apr 1979;167 4:229–36.

    CAS  PubMed  Google Scholar 

  69. Lupien SJ, McEwen BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev. Jun 1997;24 1:1–27.

    CAS  PubMed  Google Scholar 

  70. Drug-induced convulsions. Report from Boston Collaborative Drug Surveillance Program. Lancet Sep 30 1972;2 7779:677–79.

    PubMed  Google Scholar 

  71. Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest. 1989;7 5:479–91.

    CAS  PubMed  Google Scholar 

  72. Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol. Apr 1991;48 4:406–9.

    CAS  PubMed  Google Scholar 

  73. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol. Mar 1996;27 3:235–40.

    CAS  PubMed  Google Scholar 

  74. Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. Feb 1993;94 2:216–9.

    CAS  PubMed  Google Scholar 

  75. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. Mar 1 2002;20 5:1375–82.

    CAS  PubMed  Google Scholar 

  76. Cohen MH, Johnson JR, Pazdur R. Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. Oct 1 2005;11 19 Pt 1:6767–71.

    CAS  PubMed  Google Scholar 

  77. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature Aug 11 1988;334 6182:519–22.

    CAS  PubMed  Google Scholar 

  78. Thomas CF Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med. Jun 10 2004;350 24:2487–98.

    CAS  PubMed  Google Scholar 

  79. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA Nov 21 2001;286 19:2450–60.

    CAS  PubMed  Google Scholar 

  80. Clancey JK. Spinal epidural lipomatosis: a case study. J Neurosci Nurs. Aug 2004;36 4:208–9, 213.

    PubMed  Google Scholar 

  81. Zampella EJ, Duvall ER, Sekar BC, et al. Symptomatic spinal epidural lipomatosis as a complication of steroid immunosuppression in cardiac transplant patients. Report of two cases. J Neurosurg. Nov 1987;67 5:760–4.

    CAS  PubMed  Google Scholar 

  82. Smith CL. “Corticosteroid glaucoma” a summary and review of the literature. Am J Med Sci. Aug 1966;252 2:239–44.

    CAS  PubMed  Google Scholar 

  83. Sundmark E. The occurrence of posterior subcapsular cataracts in patients on long-term systemic corticosteroid therapy. Acta Ophthalmol (Copenh) 1963;41:515–23.

    CAS  Google Scholar 

  84. Black RL, Oglesby RB, Von Sallmann L, Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA Sep 10 1960;174:166–71.

    CAS  PubMed  Google Scholar 

  85. Hadjikoutis S, Morgan JE, Wild JM, Smith PE. Ocular complications of neurological therapy. Eur J Neurol. Jul 2005;12 7:499–507.

    CAS  PubMed  Google Scholar 

  86. Cersosimo RJ, Brophy MT. Hiccups with high dose dexamethasone administration: a case report. Cancer Jan 15 1998;82 2:412–4.

    CAS  PubMed  Google Scholar 

  87. Lewis JH. Hiccups: causes and cures. J Clin Gastroenterol. Dec 1985;7 6:539–52.

    CAS  PubMed  Google Scholar 

  88. Braithwaite SS, Barr WG, Rahman A, Quddusi S. Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med. Nov 1998;104 5:163–6.

    CAS  PubMed  Google Scholar 

  89. Rotstein J, Good RA. Steroid pseudorheumatism. AMA Arch Intern Med. Apr 1957;99 4:545–55.

    CAS  PubMed  Google Scholar 

  90. Josko J, Knefel K. The role of vascular endothelial growth factor in cerebral oedema formation. Folia Neuropathol. 2003;41 3:161–6.

    CAS  PubMed  Google Scholar 

  91. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. Feb 1 2007;67 2:323–6.

    CAS  PubMed  Google Scholar 

  92. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. Oct 1 2009;27 28:4733–40.

    CAS  PubMed  Google Scholar 

  93. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. Dec 2008;7 12:1152–60.

    CAS  PubMed  Google Scholar 

  94. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell Jan 2007;11 1:83–95.

    CAS  PubMed  Google Scholar 

  95. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia May–Jun 1993;34 3:453–68.

    CAS  PubMed  Google Scholar 

  96. Morris HH, Estes ML, Gilmore R, Van Ness PC, Barnett GH, Turnbull J. Chronic intractable epilepsy as the only symptom of primary brain tumor. Epilepsia Nov–Dec 1993;34 6:1038–43.

    CAS  PubMed  Google Scholar 

  97. Cascino GD. Epilepsy and brain tumors: implications for treatment. Epilepsia 1990;31 Suppl 3:S37–S44.

    PubMed  Google Scholar 

  98. Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology Nov 12 2002;59 9 Suppl 5:S21–S26.

    PubMed  Google Scholar 

  99. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol. Jul 1995;52 7:717–24.

    CAS  PubMed  Google Scholar 

  100. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology Dec 26 2006;67 12 Suppl 4:S10–S13.

    PubMed  Google Scholar 

  101. Bateman DE, Hardy JA, McDermott JR, Parker DS, Edwardson JA. Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res. Jun 1988;10 2:112–4.

    CAS  PubMed  Google Scholar 

  102. Wolf HK, Roos D, Blumcke I, Pietsch T, Wiestler OD. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol (Berl). 1996;91 4:376–84.

    CAS  Google Scholar 

  103. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci. May 2003;30 2:106–12.

    PubMed  Google Scholar 

  104. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien). 1990;103 1–2:47–51.

    CAS  Google Scholar 

  105. Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology Apr 1996;46 4:985–91.

    CAS  PubMed  Google Scholar 

  106. Lee ST, Lui TN, Chang CN, et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol. May 1989;31 5:361–4.

    CAS  PubMed  Google Scholar 

  107. North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg. May 1983;58 5:672–77.

    CAS  PubMed  Google Scholar 

  108. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. Dec 2004;79 12:1489–94.

    PubMed  Google Scholar 

  109. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia Apr 2001;42 4:515–24.

    CAS  PubMed  Google Scholar 

  110. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology May 23 2000;54 10:1886–93.

    CAS  PubMed  Google Scholar 

  111. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. Dec 2006;20 6:1337–61.

    PubMed  Google Scholar 

  112. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA Feb 2 2005;293 5:557–64.

    CAS  PubMed  Google Scholar 

  113. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB. Phenytoin–dexamethasone interaction: a previously unreported observation. Surg Neurol. Jul 1981;16 1:23–4.

    CAS  PubMed  Google Scholar 

  114. Werk EE Jr., Choi Y, Sholiton L, Olinger C, Haque N. Interference in the effect of dexamethasone by diphenylhydantoin. N Engl J Med. Jul 3 1969;281 1:32–4.

    PubMed  Google Scholar 

  115. Sperling MR, Ko J. Seizures and brain tumors. Semin Oncol. Jun 2006;33 3:333–41.

    PubMed  Google Scholar 

  116. Dofferhoff AS, Berendsen HH, vd Naalt J, Haaxma-Reiche H, Smit EF, Postmus PE. Decreased phenytoin level after carboplatin treatment. Am J Med. Aug 1990;89 2:247–8.

    CAS  PubMed  Google Scholar 

  117. Fincham RW, Schottelius DD. Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit. 1979;1 2:277–83.

    CAS  PubMed  Google Scholar 

  118. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med. Nov 1989;87 5:505–10.

    CAS  PubMed  Google Scholar 

  119. Chang TK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther. Jul 1995;274 1:270–5.

    CAS  PubMed  Google Scholar 

  120. Prados MD, Yung WK, Jaeckle KA, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-oncol Jan 2004;6 1:44–54.

    CAS  PubMed  Google Scholar 

  121. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. Jul 2003;2 7:404–9.

    CAS  PubMed  Google Scholar 

  122. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. Oct 2000;68 4:356–66.

    CAS  PubMed  Google Scholar 

  123. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997;39 5:440–4.

    CAS  PubMed  Google Scholar 

  124. Camphausen K, Cerna D, Scott T, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. Apr 10 2005;114 3:380–6.

    CAS  PubMed  Google Scholar 

  125. Cascino GD. Surgical treatment for epilepsy. Epilepsy Res. Jul–Aug 2004;60 2–3:179–86.

    PubMed  Google Scholar 

  126. Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm. Nov 15 2005;62 22 Suppl 5:S.

    Google Scholar 

  127. Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir (Wien). 1991;109 3–4:93–7.

    CAS  Google Scholar 

  128. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. Mar 1983;13 3:334–6.

    CAS  PubMed  Google Scholar 

  129. Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: part I. Clinical profile. J Neurooncol. Oct 1992;14 2:119–25.

    CAS  PubMed  Google Scholar 

  130. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro-oncol Apr 2007;9 2:89–95.

    PubMed  Google Scholar 

  131. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res. Oct 2009;29 10:4309–13.

    PubMed  Google Scholar 

  132. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. Sep 1997;33 10:1592–6.

    CAS  PubMed  Google Scholar 

  133. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer Dec 15 1991;68 12:2621–4.

    CAS  PubMed  Google Scholar 

  134. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) Sep 1999;78 5:285–91.

    CAS  Google Scholar 

  135. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer Aug 1 2000;89 3:640–6.

    CAS  PubMed  Google Scholar 

  136. Sciacca FL, Ciusani E, Silvani A, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res. Feb 15 2004;10 4:1312–7.

    CAS  PubMed  Google Scholar 

  137. Tabori U, Beni-Adani L, Dvir R, et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer. Nov 2004;43 6:633–6.

    PubMed  Google Scholar 

  138. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis. May–Jun 1994;36 6:417–22.

    CAS  PubMed  Google Scholar 

  139. Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979–1998: an analysis using multiple-cause mortality data. Arch Intern Med. Jul 28 2003;163 14:1711–7.

    PubMed  Google Scholar 

  140. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet Apr 24 1999;353 9162:1386–9.

    CAS  PubMed  Google Scholar 

  141. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. Apr;5(4):692–9.

    Google Scholar 

  142. Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. Apr 2007;106 4:601–8.

    PubMed  Google Scholar 

  143. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. Mar 10 2006;24 8:1310–8.

    CAS  PubMed  Google Scholar 

  144. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med. Sep 2001;7 5:326–31.

    CAS  PubMed  Google Scholar 

  145. Thoron L, Arbit E. Hemostatic changes in patients with brain tumors. J Neurooncol. 1994;22 2:87–100.

    CAS  PubMed  Google Scholar 

  146. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer May 1 1996;77 9:1877–83.

    CAS  PubMed  Google Scholar 

  147. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost. Feb 2010;8(2):221–7.

    Google Scholar 

  148. Iberti TJ, Miller M, Abalos A, et al. Abnormal coagulation profile in brain tumor patients during surgery. Neurosurgery Mar 1994;34 3:389–94. discussion 394–385.

    CAS  PubMed  Google Scholar 

  149. Sawaya R, Highsmith RF. Postoperative venous thromboembolism and brain tumors: part III. Biochemical profile. J Neurooncol. Oct 1992;14 2:113–8.

    CAS  PubMed  Google Scholar 

  150. McRae SJ, Ginsberg JS. Update in the diagnosis of deep-vein thrombosis and pulmonary embolism. Curr Opin Anaesthesiol. Feb 2006;19 1:44–51.

    PubMed  Google Scholar 

  151. Segal JB, Eng J, Tamariz LJ, Bass EB. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. Jan–Feb 2007;5 1:63–73.

    PubMed  Google Scholar 

  152. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med. Jul 15 2004;351 3:268–77.

    CAS  PubMed  Google Scholar 

  153. Wells PS, Anderson DR, Rodger M, et al. Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. Sep 25 2003;349 13:1227–35.

    CAS  PubMed  Google Scholar 

  154. Huisman MV, Klok FA. Diagnostic management of clinically suspected acute pulmonary embolism. J Thromb Haemost. Jul 2009;7 Suppl 1:312–7.

    CAS  PubMed  Google Scholar 

  155. Bostrom S, Holmgren E, Jonsson O, et al. Post-operative thromboembolism in neurosurgery. A study on the prophylactic effect of calf muscle stimulation plus dextran compared to low-dose heparin. Acta Neurochir (Wien). 1986;80 3–4:83–9.

    CAS  Google Scholar 

  156. Bucci MN, Papadopoulos SM, Chen JC, Campbell JA, Hoff JT. Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: a randomized trial. Surg Neurol. Oct 1989;32 4:285–8.

    CAS  PubMed  Google Scholar 

  157. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery Mar 1978;83 3:354–8.

    CAS  PubMed  Google Scholar 

  158. Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med. Mar 1989;149 3:679–81.

    CAS  PubMed  Google Scholar 

  159. Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. Aug 1999;8 2:139–42.

    CAS  PubMed  Google Scholar 

  160. Flinn WR, Sandager GP, Silva MB Jr., Benjamin ME, Cerullo LJ, Taylor M. Prospective surveillance for perioperative venous thrombosis. Experience in 2643 patients. Arch Surg. May 1996;131 5:472–80.

    CAS  PubMed  Google Scholar 

  161. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. Jul 9 1998;339 2:80–5.

    CAS  PubMed  Google Scholar 

  162. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. Sep 1978;49 3:378–81.

    CAS  PubMed  Google Scholar 

  163. Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. Sep 1997;226 3:306–13. discussion 313–304.

    CAS  PubMed  Google Scholar 

  164. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. Aug 14–28 2000;160 15:2327–32.

    CAS  PubMed  Google Scholar 

  165. Carman TL, Kanner AA, Barnett GH, Deitcher SR. Prevention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J. Jan 2003;96 1:17–22.

    PubMed  Google Scholar 

  166. Stephens PH, Healy MT, Smith M, Jewkes DA. Prophylaxis against thromboembolism in neurosurgical patients: a survey of current practice in the United Kingdom. Br J Neurosurg. Apr 1995;9 2:159–63.

    CAS  PubMed  Google Scholar 

  167. Perry J, Rogers L, Laperriere N, et al. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol. 2007;25:77 s.

    Google Scholar 

  168. Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica Sep 2000;85 9:935–42.

    CAS  PubMed  Google Scholar 

  169. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. Jul 2001;88 7:913–30.

    CAS  PubMed  Google Scholar 

  170. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?. Arch Intern Med. Dec 1987;147 12:2177–9.

    CAS  PubMed  Google Scholar 

  171. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer Jan 15 1994;73 2:493–8.

    CAS  PubMed  Google Scholar 

  172. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. Mar 1987;66 3:357–8.

    CAS  PubMed  Google Scholar 

  173. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O’Fallon JR. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc. Apr 1994;69 4:329–32.

    CAS  PubMed  Google Scholar 

  174. Ruff RL, Posner JB. The incidence of systemic venous thrombosis and the risk of anticoagulation in patients with malignant gliomas. Trans Am Neurol Assoc. 1981;106:223–6.

    CAS  PubMed  Google Scholar 

  175. Pruitt AA. Treatment of medical complications in patients with brain tumors. Curr Treat Options Neurol. Jul 2005;7 4:323–36.

    PubMed  Google Scholar 

  176. Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. Dec 2004;5 6:511–7.

    PubMed  Google Scholar 

  177. Norris LK, Grossman SA. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol. 1994;22 2:127–37.

    CAS  PubMed  Google Scholar 

  178. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol. May 2002;14 3:299–307.

    PubMed  Google Scholar 

  179. Coon WW, Willis PW 3rd. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med. Mar 1974;133 3:386–92.

    CAS  PubMed  Google Scholar 

  180. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest Sep 2004;126 3 Suppl:287S–310S.

    CAS  PubMed  Google Scholar 

  181. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest Jan 2001;119 1 Suppl:64S–94S.

    CAS  PubMed  Google Scholar 

  182. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology Jun 1993;43 6:1111–4.

    CAS  PubMed  Google Scholar 

  183. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. Aug 12–26 2002;162 15:1729–35.

    CAS  PubMed  Google Scholar 

  184. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. Jul 10 2003;349 2:146–53.

    CAS  PubMed  Google Scholar 

  185. Linenberger ML, Wittkowsky AK. Thromboembolic complications of malignancy. Part 2: management. Oncology (Williston Park) Jul 2005;19 8:1077–84.

    Google Scholar 

  186. Dunn AS, Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med. Jun 1999;106 6:660–9.

    CAS  PubMed  Google Scholar 

  187. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. Mar 14 1996;334 11:682–7.

    CAS  PubMed  Google Scholar 

  188. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. Mar 14 1996;334 11:677–81.

    CAS  PubMed  Google Scholar 

  189. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. Jan 2002;116 1:178–86.

    CAS  PubMed  Google Scholar 

  190. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth. Jun–Jul 2002;49 6:S11–S25.

    PubMed  Google Scholar 

  191. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. Jan 2007;82 1:82–92.

    CAS  PubMed  Google Scholar 

  192. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2007;119 5:643–51.

    CAS  PubMed  Google Scholar 

  193. Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med. Jan–Mar 2007;53 1:17–22.

    CAS  PubMed  Google Scholar 

  194. Firozvi K, Deveras RA, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol. Aug 2006;81 8:582–9.

    CAS  PubMed  Google Scholar 

  195. Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost. Mar 2004;91 3:531–37.

    CAS  PubMed  Google Scholar 

  196. Heimans JJ, Taphoorn MJ. Impact of brain tumour treatment on quality of life. J Neurol. Aug 2002;249 8:955–60.

    PubMed  Google Scholar 

  197. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. Mar 2002;57 1:41–9.

    PubMed  Google Scholar 

  198. Osoba D, Aaronson NK, Muller M, et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol. Sep 1997;34 3:263–78.

    CAS  PubMed  Google Scholar 

  199. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncol Oct 2000;2 4:221–8.

    CAS  PubMed  Google Scholar 

  200. Salo J, Niemela A, Joukamaa M, Koivukangas J. Effect of brain tumour laterality on patients’ perceived quality of life. J Neurol Neurosurg Psychiatry. Mar 2002;72 3:373–77.

    CAS  PubMed  Google Scholar 

  201. Hickok JT, Roscoe JA, Morrow GR, Mustian K, Okunieff P, Bole CW. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer Aug 22 2005;104 8:1772–8.

    PubMed  Google Scholar 

  202. Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum. Jun 1999;26 5:921–5.

    CAS  PubMed  Google Scholar 

  203. Ashton AK. Modafinil augmentation of phenelzine for residual fatigue in dysthymia. Am J Psychiatry. Sep 2004;161 9:1716–7.

    PubMed  Google Scholar 

  204. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. Feb 2004;24 1:87–90.

    CAS  PubMed  Google Scholar 

  205. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. J Affect Disord. Aug 2004;81 2:173–8.

    CAS  PubMed  Google Scholar 

  206. Price CS, Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety. 2005;21 4:149–53.

    CAS  PubMed  Google Scholar 

  207. Kaleita TA, Wellisch DK, Graham CA, Steh B, Nghiemphu P, Ford JM, Lai A, Peak S, Cloughesy TF. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol. 2006;24 18S:1503. (abstr.).

    Google Scholar 

  208. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer. May 4 2004;90 9:1691–6.

    CAS  PubMed  Google Scholar 

  209. Correa DD. Cognitive functions in brain tumor patients. Hematol Oncol Clin North Am. Dec 2006;20 6:1363–76.

    PubMed  Google Scholar 

  210. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. Jul 1998;16 7:2522–7.

    CAS  PubMed  Google Scholar 

  211. Shaw EG, Rosdhal R, D’Agostino RB Jr., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. Mar 20 2006;24 9:1415–20.

    CAS  PubMed  Google Scholar 

  212. Lee MA, Leng ME, Tiernan EJ. Risperidone: a useful adjunct for behavioural disturbance in primary cerebral tumours. Palliat Med. May 2001;15 3:255–6.

    CAS  PubMed  Google Scholar 

  213. Thiessen B, DeAngelis LM. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol. May 1998;55 5:705–10.

    CAS  PubMed  Google Scholar 

  214. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. Mar 2004;3 3:159–68.

    PubMed  Google Scholar 

  215. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. Sep 2009;8 9:810–8.

    PubMed  Google Scholar 

  216. Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. Jul 2007;18 7:1145–51.

    CAS  PubMed  Google Scholar 

  217. Litofsky NS, Farace E, Anderson F Jr., Meyers CA, Huang W, Laws ER Jr.. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery Feb 2004;54 2:358–66. discussion 366–357.

    PubMed  Google Scholar 

  218. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol. Dec 2006;80 3:313–32.

    CAS  PubMed  Google Scholar 

  219. Francis K, van Beek J, Canova C, et al. Innate immunity and brain inflammation: the key role of complement. Expert Rev Mol Med. 2003;5:1–19.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Jan Drappatz & Patrick Y.C. Wen MD

Authors
  1. Jan Drappatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Y.C. Wen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Drappatz .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, Massachusetts, USA

    Andrew D. Norden

  2. Departments of Surgery and Pediatrics, Duke University Medical Center, Durham, 27710, North Carolina, USA

    David A. Reardon

  3. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, Massachusetts, USA

    Patrick C. Y. Wen

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Drappatz, J., Wen, P.Y. (2011). Principles of Supportive Care. In: Norden, A., Reardon, D., Wen, P. (eds) Primary Central Nervous System Tumors. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60761-166-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-166-0_4

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-165-3

  • Online ISBN: 978-1-60761-166-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation